Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Healthtrust
McKinsey
Teva
McKesson
Federal Trade Commission
Harvard Business School
Chinese Patent Office
Colorcon

Generated: August 19, 2018

DrugPatentWatch Database Preview

Midatech Pharma Us Company Profile

« Back to Dashboard

What is the competitive landscape for MIDATECH PHARMA US, and when can generic versions of MIDATECH PHARMA US drugs launch?

MIDATECH PHARMA US has three approved drugs.

There are six US patents protecting MIDATECH PHARMA US drugs.

There are forty patent family members on MIDATECH PHARMA US drugs in nineteen countries.

Summary for Midatech Pharma Us
International Patents:40
US Patents:6
Tradenames:3
Ingredients:3
NDAs:3

Drugs and US Patents for Midatech Pharma Us

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Midatech Pharma Us ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes 8,518,442 ➤ Try a Free Trial Y ➤ Try a Free Trial
Midatech Pharma Us ZUPLENZ ondansetron FILM;ORAL 022524-001 Jul 2, 2010 RX Yes No 8,580,830 ➤ Try a Free Trial Y ➤ Try a Free Trial
Midatech Pharma Us ZUPLENZ ondansetron FILM;ORAL 022524-002 Jul 2, 2010 RX Yes Yes 9,095,577 ➤ Try a Free Trial Y ➤ Try a Free Trial
Midatech Pharma Us SOLTAMOX tamoxifen citrate SOLUTION;ORAL 021807-001 Oct 29, 2005 RX No No 6,127,425 ➤ Try a Free Trial Y ➤ Try a Free Trial
Midatech Pharma Us ORAVIG miconazole TABLET;BUCCAL 022404-001 Apr 16, 2010 RX Yes Yes 6,916,485 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Midatech Pharma Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,682,037 Non-mucoadhesive film dosage forms ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Fuji
Dow
Baxter
Queensland Health
Boehringer Ingelheim
QuintilesIMS
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.